296 related articles for article (PubMed ID: 22743037)
1. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.
Vandergeeten C; Fromentin R; Chomont N
Cytokine Growth Factor Rev; 2012; 23(4-5):143-9. PubMed ID: 22743037
[TBL] [Abstract][Full Text] [Related]
2. The challenge of viral reservoirs in HIV-1 infection.
Blankson JN; Persaud D; Siliciano RF
Annu Rev Med; 2002; 53():557-93. PubMed ID: 11818490
[TBL] [Abstract][Full Text] [Related]
3. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
4. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
[TBL] [Abstract][Full Text] [Related]
5. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
6. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.
North TW; Higgins J; Deere JD; Hayes TL; Villalobos A; Adamson L; Shacklett BL; Schinazi RF; Luciw PA
J Virol; 2010 Mar; 84(6):2913-22. PubMed ID: 20032180
[TBL] [Abstract][Full Text] [Related]
7. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
Forde J; Volpe JM; Ciupe SM
Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
[TBL] [Abstract][Full Text] [Related]
8. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
10. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
Front Immunol; 2021; 12():720697. PubMed ID: 34531866
[TBL] [Abstract][Full Text] [Related]
11. Barriers to HIV Cure.
Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
[TBL] [Abstract][Full Text] [Related]
12. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
[TBL] [Abstract][Full Text] [Related]
13. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.
Reeves DB; Duke ER; Wagner TA; Palmer SE; Spivak AM; Schiffer JT
Nat Commun; 2018 Nov; 9(1):4811. PubMed ID: 30446650
[TBL] [Abstract][Full Text] [Related]
14. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.
Chomont N; El-Far M; Ancuta P; Trautmann L; Procopio FA; Yassine-Diab B; Boucher G; Boulassel MR; Ghattas G; Brenchley JM; Schacker TW; Hill BJ; Douek DC; Routy JP; Haddad EK; Sékaly RP
Nat Med; 2009 Aug; 15(8):893-900. PubMed ID: 19543283
[TBL] [Abstract][Full Text] [Related]
15. The multifaceted nature of HIV latency.
Dufour C; Gantner P; Fromentin R; Chomont N
J Clin Invest; 2020 Jul; 130(7):3381-3390. PubMed ID: 32609095
[TBL] [Abstract][Full Text] [Related]
16. Residual inflammation and viral reservoirs: alliance against an HIV cure.
Massanella M; Fromentin R; Chomont N
Curr Opin HIV AIDS; 2016 Mar; 11(2):234-41. PubMed ID: 26575148
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Latent Reservoir for HIV-1.
Sengupta S; Siliciano RF
Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
[TBL] [Abstract][Full Text] [Related]
18. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.
Shen L; Siliciano RF
J Allergy Clin Immunol; 2008 Jul; 122(1):22-8. PubMed ID: 18602567
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
[TBL] [Abstract][Full Text] [Related]
20. Toward HIV eradication or remission: the tasks ahead.
Ho DD
Science; 1998 Jun; 280(5371):1866-7. PubMed ID: 9669944
[No Abstract] [Full Text] [Related]
[Next] [New Search]
